March 5, 2021

Tocilizumab plus Standard Care versus Standard Care in Patients in India with Moderate to Severe COVID-19-Associated Cytokine Release Syndrome (COVINTOC): An Open-Label, Multicentre, Randomised, Controlled, Phase 3 Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A multi-center, phase-3, randomized trial among patients (n=180) with moderate to severe COVID-19 conducted at 12 hospitals across India of the anti-IL-6 receptor monoclonal antibody treatment tocilizumab found no significant difference in the proportion of patients with progressive COVID-19 up to day 14 between the treatment group compared to standard care group (9% vs 13%). No significant difference between the two groups was observed in the secondary endpoints, as well as the proportion of patients experiencing adverse events, serious adverse events, or death.

Soin et al. (Mar 4, 2021). Tocilizumab plus Standard Care versus Standard Care in Patients in India with Moderate to Severe COVID-19-Associated Cytokine Release Syndrome (COVINTOC): An Open-Label, Multicentre, Randomised, Controlled, Phase 3 Trial. The Lancet Respiratory Medicine. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00081-3/fulltext